Thai Leaf Biotechnology, a private company that imports and produces hemp seed, in collaboration with Cornell University, has unveiled plans to upgrade the Thai hemp market by developing new strains of hemp and seeds that are suitable to be grown in Thailand's climate as well as yielding a high cannabidiol (CBD) content.
The firm is working on three core categories -- beverages, food supplements and cosmetics -- and will later include pharmaceutical products.
Yingyos Charubusapayon, chief executive of Thai Leaf Biotechnology, said his company has set a market share target of 10% and plans to become the leader of the Asian hemp-based pharmaceutical market in the future.
